Navigation Links
92 Medicines and Vaccines now in Development for HIV/AIDS
Date:11/20/2007

WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- Pharmaceutical researchers are testing 92 medicines and vaccines to treat or prevent HIV/AIDS and related conditions, according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA). December 1 marks the 20th anniversary of "World AIDS Day" -- a global awareness campaign that originated at the 1988 World Summit of Ministers of Health on Programmes for AIDS Prevention.

"We are greatly encouraged by the new, critically-important medicines and vaccines in development to treat and prevent HIV infection," says PhRMA President and CEO Billy Tauzin. "Pharmaceutical researchers are continuing their efforts to develop new therapies and vaccines to improve and lengthen the lives of HIV-infected patients."

The report found that of the 92 products in development, researchers are studying 20 vaccines and 46 antivirals. These drugs are either in human clinical trials or await approval by the U.S. Food and Drug Administration.

The report also lists 30 medicines to treat HIV/AIDS that have been approved since the virus that causes AIDS was first identified more than 20 years ago. The first such medicine was developed in 1987, just four years after the HIV virus was identified. The increased availability and utilization of newer prescription medicines has helped to reduce the U.S. death rate from AIDS substantially in recent years, according to government statistics.

Despite that progress, AIDS remains a devastating and growing worldwide health problem in developing countries, particularly in sub-Saharan Africa, China, India and the Russian Federation. According to the Joint United Nations Programme on HIV/AIDS, an estimated 32.7 million people worldwide lived with HIV at the end of 2006.

This year, that figure grew to an estimated 33.2 million people living with HIV, with an estimated 2.1 million people newly infected in 2007.

From 2000 to 2006, A
'/>"/>

SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
2. Concentra Offers Flu Vaccines to Keep America Working
3. Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Promising Cystic Fibrosis Compound on Track for Development
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
11. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)...alif., Nov. 20 Bionovo, ... present results from the Phase 1B,clinical trial...tic breast,cancer, BZL101, at the Society for Int...e in Atlanta, Georgia. The Company,s oral present...will be presented as a part of the Best of the,SI...
(Date:11/20/2008)...20 PAREXEL International...iopharmaceutical services provider, today announce...ovide regulatory consulting and clinical research ..., PAREXEL now has locations throughout five import...ich also include Argentina, Brazil, Chile, and Mex...
(Date:11/19/2008)...tudy did not achieve statistical significance , ...l/ -- Pharmos Corporation (Nasdaq: PARS ) today ... of its topical NanoEmulsion (NE) drug delivery te...ine. , , The multi-center, randomized, doub... safety and efficacy of the Company,s 3% Diclofena...
(Date:11/19/2008)...Million Payment from Roche- , , MONTVALE, N...maceuticals Corp. (Nasdaq: MEMY ) today announce... Phase 2 trial of R3487/MEM 3454, its lead alpha-7...nt associated with schizophrenia (CIAS). The Comp...al, triggering a $5.0 million payment from its par...
Breaking Medicine Technology:Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3Almost Family Reports Third Quarter 2008 Results 28817 1Almost Family Reports Third Quarter 2008 Results 28817 2Almost Family Reports Third Quarter 2008 Results 28817 3Almost Family Reports Third Quarter 2008 Results 28817 4Almost Family Reports Third Quarter 2008 Results 28817 5Almost Family Reports Third Quarter 2008 Results 28817 6Almost Family Reports Third Quarter 2008 Results 28817 7Almost Family Reports Third Quarter 2008 Results 28817 8Almost Family Reports Third Quarter 2008 Results 28817 9Almost Family Reports Third Quarter 2008 Results 28817 10Almost Family Reports Third Quarter 2008 Results 28817 11Almost Family Reports Third Quarter 2008 Results 28817 12Almost Family Reports Third Quarter 2008 Results 28817 13Almost Family Reports Third Quarter 2008 Results 28817 14Almost Family Reports Third Quarter 2008 Results 28817 15Almost Family Reports Third Quarter 2008 Results 28817 16InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 1InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 2InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 3InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 4InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 5InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 6InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 7InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 8InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 9InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 10InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 11Neurobiological Technologies to Present at the Rodman 26 Renshaw 10th Annual Healthcare Conference in New York on November 10 8897 1Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 1Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 2Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 3Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 4Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 5Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 6
...E)--Apr 19, 2007 - Gilead Sciences, Inc.,(Nasdaq:G... III,AIR-CF2 study evaluating aztreonam lysine for...c fibrosis (CF) who have,pulmonary Pseudomonas aer...eatment course of aztreonam lysine significantly i...s (IV) antibiotics versus,placebo. All patients re...
... WIRE)--Apr 23, 2007 - CytRx Corporation,(NASDAQ:C...Ai),delivery technology exclusively licensed to it...orporation (RXi), has been,published in the April ... Chemical Biology. The technology was developed by...and University of,Massachusetts Medical School (UM...
Other Medicine Technology:Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 2Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 3Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 5Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 6Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 7CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 2CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 4
(Date:11/21/2008)...Call/ -- The Providence Service,Corporation (Nasd... the Company,s,Chief Operating Officer, has been ...r. Norris, appointment fills the vacancy left by t...nd returns the board to six members. Mr.,Norris ... Mr. Norris, age 41, has been with Providence ...
(Date:11/21/2008)...ainst Lennox-Gastaut syndrome , , FRIDAY...nzel (rufinamide) has been approved as a supplemen...d Lennox-Gastaut syndrome, the U.S. Food and Drug ... was based on results of a four-month clinical tri...o patients who took a placebo, those who took the ...
(Date:11/21/2008)...SNewswire/ -- New research at West Virginia Unive...tobacco product aimed at young adults is catching ...s, Camel Snus - touted as a socially acceptable wa...h levels of nicotine. , , "Camel Snus conta... said Bruce Adkins of the state Division of Tobacc...
(Date:11/21/2008)...wswire/ -- U.S. News & World Report and the Na...ed BlueChoice(R) HealthPlan of South Carolina in t...ublished in U.S. News & World Report,s issue t...ranks the nation,s best health plans based on clin...tation scores. NCQA and U.S. News & World Repo...
Breaking Medicine News(10 mins):Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2
...n Parry, a 59 year old British grandmother is all ...India after undergoing a surgery// in the Indian c...ial Hospital has cured her of a painful back. Parr...to get the treatment on the UK’s National Health S...
...rwegian study has revealed that anti-depressants l...y inflict damage upon the human skeleton.// The No...NU) researcher Bjorn I. Gustafsson has revealed th...he activity of bone building cells, while raising ...
...archers at the University of North Carolina at Cha...aggressive prostate tumors. The molecule//, labele...ily and triggers aggressiveness in prostate tumors...recting cells to dump a tumor-suppressor protein. ...
...archers have found that exposure to pollutants inc...study was conducted on fisherman families eating//...nd pollutants known as Persistent Organochlorine P... biphenyls (PCBs) and DDT. Type 2 diabetes genera...
Other Medicine News:Health News:Indian Healthcare Facilities Come In For Praise 2
The HEMOCHRON Jr. Signature+ Microcoagulation System offers point-of-care monitoring with numerous features to meet the needs of each individual department, as well as the needs of regulatory complia
Inquire
...'000 tests per year through automatic scheduling a... processing up to 4 assays on 4 plates simultaneou...to presentation of the results, are controlled by ... tube rack) and 256 (POS-ID Linear Rack) samples c...
IMMULITE 2000 assays are designed for use with the IMMULITE 2000, a high-throughput, continuous random access immunoassay analyzer. IMMULITE 2000 offers testing efficiency through centralization, and
Medicine Products: